0000000000120041

AUTHOR

Loredana Bruno

showing 34 related works from this author

Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?

2007

Various studies have been published in Italy regarding the different BRCA1 mutations, but only the BRCA1-5083del19 mutation is recurrent and specific to individuals of Italian descent with a founder effect on the Calabrian population. In our previous study, BRCA1-5083del19 mutation carriers were found in four index cases of 106 Sicilian patients selected for familial and/or hereditary breast/ovarian cancers. The high frequency rate of this mutation identified in the Sicilian population led us to perform haplotype analysis in all family carriers. Five highly polymorphic microsatellite markers were used (D17S1320, D17S932, D17S1323, D17S1326, D17S1325) to establish whether or not all these fa…

MaleCancer ResearchSettore MED/06 - Oncologia MedicaPopulationBRCA1 breast cancerBreast NeoplasmsBiologyRisk AssessmentAllelotype AnalysisReference ValuesHumansAlleleeducationSicilySequence DeletionOvarian NeoplasmsGeneticseducation.field_of_studyBRCA1 ProteinHaplotypeFounder Effectlanguage.human_languagePedigreeOncologyMutationMutation (genetic algorithm)languageMicrosatelliteFemaleSicilianMicrosatellite RepeatsFounder effect
researchProduct

Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (G…

2006

Background Methylation of the p16 promoter is one of the most frequent mechanisms of gene inactivation; its incidence is extremely variable according to the type of tumor involved. Our purpose was to analyze the hypermethylation of the p16 promoter in laryngeal squamous cell carcinomas (LSCC), salivary gland (SG) tumors and in colorectal cancer (CRC), to detect any possible association with the clinicopathological features and to determine the prognostic significance of the p16 gene in the tumors analyzed. Patients and methods The hypermethylation of the p16 promoter was prospectively analyzed, by MSP, in a consecutive series of 64 locally advanced LSCC patients, in a consecutive series of …

Oncologymedicine.medical_specialtyColorectal cancerInternal medicinemedicineHumansPromoter Regions GeneticProspective cohort studyNeoplasm StagingUnivariate analysisbusiness.industryGenes p16Incidence (epidemiology)CancerHematologyMethylationDNA Methylationmedicine.diseaseOncologyHead and Neck NeoplasmsSalivary gland cancerDNA methylationCarcinoma Squamous CellColorectal NeoplasmsbusinessP16INK4A head and neck carcinoma
researchProduct

4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).

2007

Various studies have been published in Italy regarding the different BRCA1 mutations, but only the BRCA1-5083del19 mutation is recurrent and specific to individuals of Italian descent with a founder effect on the Calabrian population. In our previous study, BRCA1-5083del19 mutation carriers were found in four index cases of 106 Sicilian patients selected for familial and/or hereditary breast/ovarian cancers. The high frequency rate of this mutation identified in the Sicilian population led us to perform haplotype analysis in all family carriers. Five highly polymorphic microsatellite markers were used (D17S1320, D17S932, D17S1323, D17S1326, D17S1325) to establish whether or not all these fa…

MaleBRCA1 gene Founder mutation Haplotype analysis Hereditary breast and ovarian cancer Sicilian patientsSettore MED/06 - Oncologia MedicaGenetic counselingPopulationDNA Mutational AnalysisGenes BRCA1Single-nucleotide polymorphismBreast NeoplasmsBiologyBRCA1 geneHaplotype analysiHumansAlleleeducationAllelotypeFounder mutationSicilyGeneticsOvarian Neoplasmseducation.field_of_studyHaplotypeHematologylanguage.human_languageFounder EffectPedigreeOncologyHaplotypesHaplotype frequencylanguageFemaleSicilianGene DeletionFounder effectGenetic counselingMicrosatellite Repeats
researchProduct

Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico…

2006

Background Over 600 different pathogenic mutations have been identified in the BRCA1 gene. Nevertheless, numerous missense mutations of unknown biological function still exist. Understanding of biological significance of these mutations should help in genetic counselling to carriers and their families. Patients and methods A total of 104 patients with breast and/or ovarian cancer whose genetic counselling answered the criteria of the American Society of Clinical Oncology (ASCO 2003), were prospectively screened for mutations in all coding exons of the BRCA1 gene by automatic direct sequencing. Results During these mutational screening procedures one case presented three mutations classified…

ProbandAdultmedicine.medical_specialtyProtein ConformationGenetic counselingGenes BRCA1Mutation MissenseBreast NeoplasmsGenetic CounselingExonBreast cancermedicineMissense mutationHumansProspective StudiesGeneSicilyScreening proceduresGerm-Line MutationGynecologyGeneticsFamily HealthOvarian Neoplasmsbusiness.industryBRCA1 ProteinGenetic VariationHematologyDNA NeoplasmExonsmedicine.diseasePedigreeOncologyFemalebusinessOvarian cancerAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

79 VUS VARIANTS IN BRCA GENES OF HEREDITARY BREAST/OVARIAN CANCER

2010

OncologyBreast ovarian cancermedicine.medical_specialtyOncologybusiness.industryInternal medicinemedicineRadiology Nuclear Medicine and imagingGeneral MedicinebusinessBrca genesCancer Treatment Reviews
researchProduct

A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer

2005

A group of 103 sicilian patients with hereditary and familiar breast and/or ovarian cancer were screened for Breast Cancer 1 gene (BRCA1) mutations by direct sequencing PCR products spanning the coding region and partial intronic regions of the BRCA1 gene. In this study, we report a new germline mutation in BRCA1 gene, not previously reported in the BIC database, in a woman with ovarian cancer at 46 years old. Mother's proband has been diagnosed the same histotype of ovarian cancer at 42 age. The mutational analyses that shown a 4843delC frameshift mutation in exon 16 of BRCA1 gene was extended to other family members including the proband's brother and her two sons. Direct automatic sequen…

AdultMaleProbandcongenital hereditary and neonatal diseases and abnormalitiesCancer Researchendocrine system diseasesGenetic counselingCystadenocarcinomaGenes BRCA1BiologyFrameshift mutationExonGermline mutationBreast cancermedicineHumansGenetic Predisposition to DiseaseFrameshift MutationSicilyGerm-Line MutationOvarian NeoplasmsBRCA1 Direct automatic sequencing Germline mutation Ovarian cancerGeneticsMiddle Agedmedicine.diseasePedigreeOncologyMutation (genetic algorithm)Cancer researchFemaleOvarian cancerBreast Cancer Research and Treatment
researchProduct

The Clinical Significance of Unknown Sequence Variants in BRCA Genes.

2010

Abstract: Germline mutations in BRCA1/2 genes are responsible for a large proportion of hereditary breast and/or ovarian cancers. Many highly penetrant predisposition alleles have been identified and include frameshift or nonsense mutations that lead to the translation of a truncated protein. Other alleles contain missense mutations, which result in amino acid substitution and intronic variants with splicing effect. The discovery of variants of uncertain/unclassified significance (VUS) is a result that can complicate rather than improve the risk assessment process. VUSs are mainly missense mutations, but also include a number of intronic variants and in-frame deletions and insertions. Over …

GeneticsCancer ResearchBRCA genesNonsense mutationReviewBiologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282oncogenetic counselingFrameshift mutationintegrated modelsGermline mutationOncologyvariantRNA splicingMissense mutationClinical significanceAlleleGeneCancers
researchProduct

Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis…

2006

BACKGROUND:Despite the improvement in detection and surgical therapy in the last years, the outcome of patients affected by colorectal carcinoma (CRC) remains limited by metastatic relapse. The aim of this study was to investigate the presence of free tumor DNA in the plasma of CRC patients in order to understand its possible prognostic role. PATIENTS AND METHODS: Ki-Ras, TP53 mutations and p16(INK4A) methylation status were prospectively evaluated in tumor tissues and plasma of 66 CRC patients. RESULTS: In 50 of the 66 primitive tumor cases (76%) at least one significant alteration was identified in Ki-Ras and/or TP53 and/or p16(INK4A) genes. Eighteen of the 50 patients presented the same …

MaleOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaColorectal cancerColorectal carcinoma Free-cell DNA Ki-Ras TP53DiseasePolymerase Chain ReactionInternal medicinePromoter methylationHumansMedicineProspective StudiesPromoter Regions GeneticProspective cohort studyneoplasmsPolymorphism Single-Stranded ConformationalAgedNeoplasm StagingP16 geneUnivariate analysisbusiness.industryGenes p16DNA NeoplasmHematologyMethylationDNA MethylationGenes p53Prognosismedicine.diseaseGenes rasOncologyCell-free fetal DNAFemaleColorectal NeoplasmsbusinessAnnals of Oncology
researchProduct

Role of S128R polymorphism of E-selectin in colon metastasis formation.

2007

The extravasation of cancer cells is a key step of the metastatic cascade. Polymorphisms in genes encoding adhesion molecules can facilitate metastasis by increasing the strength of interaction between tumor and endothelial cells as well as impacting other properties of cancer cells. We investigated the Ser128Arg (a561c at the nucleotide level) polymorphism in the E-selectin gene in patients with metastatic colon cancer and its functional significance. Genotyping for a561c polymorphism was performed on 172 cancer patients and on an age-matched control population. The colon cancer group was divided into groups with (M+) and without observable metastasis (M−). For in vitro functional assays, …

MaleCancer ResearchColorectal cancerBiologyArginineTransfectionMetastasise-SELECTIN; COLON CANCER METASTASISSettore BIO/13 - Biologia ApplicataCell MovementE-selectinmedicineCell AdhesionSerineTumor Cells CulturedHumansNeoplasm MetastasisPolymorphism GeneticCell adhesion moleculeCancerTransfectionMiddle Agedmedicine.diseaseExtravasationColon Carcinoma E-Selectin Metastasis PolymorphismPhenotypeOncologyImmunologyCancer cellColonic NeoplasmsCancer researchbiology.proteinFemaleE-SelectinSignal TransductionInternational journal of cancer
researchProduct

Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary resu…

2006

BACKGROUND: Mammaglobin is expressed mainly in mammary tissue, overexpressed in breast cancer (BC) and rarely in other tissue. The aim of this study was to assess the sensitivity and specificity of transcript MGB1 detection and to evaluate the role of MGB1 as potential clinical marker for the detection of disseminated cancer cells in the blood of BC patients. PATIENTS AND METHODS: A consecutive series of 23 BC tissues, 36 peripheral blood BC samples and 35 healthy peripheral blood samples was prospectively recruited to investigate MGB1 expression by means of a quantitative Real Time RT-PCR assay. RESULTS: MGB1 overexpression in tissue samples of BC patients is significantly associated only …

OncologyAdultmedicine.medical_specialtyPathologySettore MED/06 - Oncologia MedicaMrna expressionClinical markerBreast NeoplasmsSensitivity and SpecificityMammaglobinBreast cancerInternal medicinemedicineBiomarkers TumorHumansUteroglobinProspective StudiesRNA MessengerProspective cohort studyAgedAged 80 and overbiologybusiness.industryReverse Transcriptase Polymerase Chain ReactionMammaglobin AMammary tissuemammaglobyn brest cancerHematologyMiddle Agedmedicine.diseaseNeoplastic Cells CirculatingPeripheral bloodNeoplasm ProteinsOncologybiology.proteinFemalebusinessDisseminated cancer
researchProduct

TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas.

2006

The putative role of TP53 and p16INK4A tumor suppressor genes and Ras oncogenes in the development and progression of salivary gland neoplasias was studied in 28 cases of pleomorphic adenomas (PA), 4 cases of cystic adenocarcinomas, and 1 case of carcinoma ex-PA. Genetic and epigenetic alterations in the above genes were analyzed by Polymerase Chain Reaction/Single Strand Conformational Polymorphism (PCR/SSCP) and sequencing and by Methylation Specific-PCR (MS-PCR). Mutations in TP53 were found in 14% (4/28) of PAs and in 60% (3/5) of carcinomas. Mutations in H-Ras and K-Ras were identified in4%(1/28) and7% (2/28) of PAs, respectively. Only 20% (1/5) of carcinomas screened displayed mutatio…

AdenomaAdenomaGenotypePhysiologyClinical BiochemistryBiologymedicine.disease_causeMethylationEpigenesis GeneticProto-Oncogene Proteins p21(ras)GenotypemedicineCarcinomaHumansEpigeneticsTP53GeneCyclin-Dependent Kinase Inhibitor p16Base SequenceSingle-strand conformation polymorphismCell BiologyMethylationmedicine.diseaseMolecular biologyCell Transformation NeoplasticMutationDisease ProgressionTumor Suppressor Protein p53Carcinogenesis
researchProduct

TP 53, H-K-Ras, P16INK4A gene molecular analysis in salivary gland tumors.

2006

researchProduct

Hereditary ovarian cancer.

2008

Apoptosis is a form of cell death that permits the removal of damaged, senescent or unwanted cells in multicellular organisms, without damage to the cellular microenvironment. Defective apoptosis represents a major causative factor in the development and progression of cancer. The majority of chemotherapeutic agents, as well as radiation, utilize the apoptotic pathway to induce cancer cell death. Resistance to standard chemotherapeutic strategies also seems to be due to alterations in the apoptotic pathway of cancer cells. Recent knowledge on apoptosis has provided the basis for novel targeted therapies that exploit apoptosis to treat cancer. These new target include those acting in the ext…

Oncologymedicine.medical_specialtyendocrine system diseasesColorectal cancerMLH1Germline mutationNeoplastic Syndromes HereditaryInternal medicineGenetic predispositionMedicineHumansGenetic Predisposition to DiseaseGenetic testingOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryBRCA mutationHematologymedicine.diseasePrognosisfemale genital diseases and pregnancy complicationsovarian cancerOncologyMSH2FemalebusinessOvarian cancer
researchProduct

Abstract 448: Molecular analysis of BRAF gene and PTEN gene expression in metastatic colorectal cancer patients: Feasibility study

2014

Abstract Introduction There are numerous causes triggering CRC. 25-80% of CRC shown a deregulation in Epidermal Growth Factor Receptor (EGFR) pathway. Two signaling pathways downstream of the EGFR are dysregulated in CRC the mitogen-activated protein kinase (MAPK) and the phosphoinositide-3-kinase (PI3K) pathway. Activating mutations in KRAS and BRAF (MAPK pathway) and PIK3CA affect prognosis and/or response to anti-EGFR MoAb. PTEN is a downstream effector of EGFR pathway and is involved in PI3K pathway. Loss of PTEN protein expression can occur through epigenetic silencing and mutation or allelic loss. Immunohistochemistry (IHC) is the most effective way to assay for loss of PTEN expressio…

Neuroblastoma RAS viral oncogene homologCancer ResearchPredictive markerbiologyColorectal cancerCancermedicine.diseasemedicine.disease_causeOncologyCancer researchTaqManmedicinebiology.proteinPTENKRASPI3K/AKT/mTOR pathwayCancer Research
researchProduct

BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.

2007

PURPOSE: To evaluate the contribution of germline BRCA1 mutations in the incidence of hereditary and familial Breast Cancer (BC) and/or Ovarian Cancer (OC) in patients from Southern Italy (in the region of Sicily) and to identify a possible association between the higher frequency of BRCA1 mutations and a specific familial profile. EXPERIMENTAL DESIGN: A consecutive series of 650 patients with BC and/or OC diagnosed between 1999 and 2005 were recruited from the Southern Italian region of Sicily, after interview at the "Regional Reference Centre for the Characterization and Genetic Screening of Hereditary Tumors" at the University of Palermo. Genetic counselling allowed us to recruit a total…

AdultMaleCancer ResearchGenetic counselingDNA Mutational AnalysisBreast NeoplasmsBiologymedicine.disease_causeGermlineBreast cancermedicineHumansGenetic Predisposition to DiseaseGenetic TestingGenetic testingAgedGeneticsOvarian NeoplasmsMutationPolymorphism Geneticmedicine.diagnostic_testBase SequenceBRCA1 ProteinBRCA1 Genetic testing Breast cancer Ovarian canceCancerMiddle Agedmedicine.diseasePedigreeOncologyItalyMutationFemaleAge of onsetFounder effectBreast cancer research and treatment
researchProduct

TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma

2005

ToprospectivelyevaluatetheprognosticsignificanceofTP53,H-,K-,andN-Rasmutations,DNA-ploidyandS-phasefraction(SPF) in patients affected by locally advanced laryngeal squamous cell carcinoma (LSCC). Eight-one patients (median follow-up was 71 months) who underwent resective surgery for primary operable locally advanced LSCC were analyzed. Tumor DNA was screened for mutational analysis by PCR/SSCP and sequencing. DNA-ploidy and SPF were performed byflow cytometric analyses. Thirty-six patients (44%) had, at least, a mutation in the TP53 gene. Of them, 22% (8/36) had double mutations and 3% (1/36) had triplemutations.Intotal,46TP53mutationswereobserved.Themajority(41%)oftheseoccurinexon5(19/46),…

Geneticsmedicine.medical_specialtyMutationPhysiologyClinical BiochemistrySingle-strand conformation polymorphismCell BiologyBiologyTp53 mutationLaryngeal squamous cell carcinomamedicine.disease_causeGastroenterologyExonInternal medicinemedicineS-Phase FractionGeneDna ploidyJournal of Cellular Physiology
researchProduct

TP53 mutations and S-Phase fraction are independent prognostic indicators in locally advanced laryngeal squamous cell carcinoma

2005

Larynx tumor is a rare neoplasia that represent only the 2% of all human tumor. In particular, the 90% of tumor that occur in this organ correspond to the laryngeal squamous cell carcinoma (LSCC). From the biomolecular point of view, it was shown that the TP53 gene mutations are the most common events observed in the early phases of LSCC carcinogenesis. However, them prognostic significance remains controversial. Besides, the prognostic significance of DNA ploidy has been well established for other solid tumors, but its role in LSCC is still controversial. The aim of this study was, therefore, to prospectively evaluate the prognostic significance of TP53 mutations, DNA-ploidy and S-phase fr…

researchProduct

Downregulated expression of Cdc25A gene in MCF-7 breast cancer cell

2009

breast cancer
researchProduct

KRAS: one actor, many potential roles in diagnosis

2014

KRAS
researchProduct

BRCA1 and BRCA2 variants of uncertain clinical significance and their implications for genetic counseling

2009

genetic counselinggermline mutation
researchProduct

BRCA1 and BRCA2 germline mutations in sicilian breast and/or ovarian cancer families and their association with familial profiles

2009

breast cancerovarian cancergermline mutation
researchProduct

EGF Induces STAT3-Dependent VEGF Expression in HT-29 colon cancer cells

2009

colon cancerEGF
researchProduct

The prognostic role of TP53 mutations in advanced laryngeal squamous cell carcinoma (LSCC).

2005

researchProduct

Analysis of Ki-ras mutations in stage I rectal carcinomas and respective regional lymphonodes

2005

researchProduct

A study of a new germline mutation in BRCA1 gene in two Sicilian families: a founder mutation?

2006

researchProduct

A missense mutation associated to early onset breast cancer in a sicilian woman.

2006

researchProduct

Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations

2013

<b><i>Objectives:</i></b> The rapid fatality of pancreatic cancer is, in large part, the result of diagnosis at an advanced stage in the majority of patients. Identification of individuals at risk of developing pancreatic adenocarcinoma would be useful to improve the prognosis of this disease. There is presently no biological or genetic indicator allowing the detection of patients at risk. Our main goal was to identify copy number variants (CNVs) common to all patients with sporadic pancreatic cancer. <b><i>Methods:</i></b> We analyzed gene CNVs in leukocyte DNA from 31 patients with sporadic pancreatic adenocarcinoma and from 93 matched contr…

OncologyMaleCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia MedicaGene DosageCancer-associated genesBiologyAdenocarcinomaGene dosagePolymorphism Single NucleotideSensitivity and SpecificityGermlineGermline mutationGermline alterationsPolymorphism (computer science)Internal medicinePancreatic cancermedicinepancreatic adenocarcinomaHumansGenetic Predisposition to DiseaseCopy number variationsCopy-number variationGerm-Line MutationGermline alterationAgedCancer-associated geneCopy number variations; Cancer-associated genes; Germline alterations; Sporadic pancreatic cancerCopy number variationCase-control studyGeneral MedicineDNA NeoplasmMiddle Agedmedicine.diseasePancreatic NeoplasmsSporadic pancreatic cancerOncologyTissue Array AnalysisCase-Control StudiesAdenocarcinomaFemale
researchProduct

TP53 in exon 5 and s-Phase fraction but not mutations in Ras gen family and DNA-ploidy are indipendent indicators in laryngeal squamous cell carcinoma

2005

researchProduct

Mutational analysis of BRCA1 gene in sicilian patient at risk for inherited breast and/or ovarian cancer: experience of reference center the biomolec…

2005

researchProduct

BRCA1 germline mutations in Sicilian breast and/or ovarian cancer families and their implications for genetic counselling.

2006

researchProduct

VUS variants in BRCA genes of hereditary breast/ovarian cancer

2010

VUS breast ovarian cancere
researchProduct

TP53 mutation are not prognostic indipendent indicators in bladder cancer

2005

researchProduct

TP53, H-K-RAS, P16INK4A GENE MOLECULAR ANALYSIS IN SALIVARY GLAND TUMORS

2007

researchProduct

Detection of free-circulating tumor DNA in plasma of patients with gastrointestinal cancer.

2005

researchProduct